Sangamo Therapeutics (SGMOQ) Current Assets (2010 - 2025)

Sangamo Therapeutics' Current Assets history runs 16 years deep, the most recent figure standing at $35.8 million for Q4 2025.

• On a quarterly basis, Current Assets fell 30.68% year-over-year to $35.8 million in Q4 2025; TTM through Dec 2025 was $35.8 million, a 30.68% decrease from a year earlier, with the FY2025 full-year figure at $35.8 million, down 30.68% from the prior year.
• Current Assets retreated to $35.8 million in Q4 2025 per SGMOQ's latest filing, from $44.1 million in the prior quarter.
• Across five years, Current Assets topped out at $606.9 million in Q1 2021 and bottomed at $35.8 million in Q4 2025.
• The 5-year median for Current Assets is $153.6 million (2023), against an average of $217.1 million.
• Across the five-year window, Current Assets jumped 63.62% in 2021 and tumbled 74.89% in 2024, its largest moves.
• Year by year, Current Assets stood at $398.8 million in 2021, then declined by 24.69% to $300.3 million in 2022, then tumbled by 68.59% to $94.3 million in 2023, then sank by 45.2% to $51.7 million in 2024, then plunged by 30.68% to $35.8 million in 2025.
• Per Business Quant, the three latest SGMOQ Current Assets figures stand at $35.8 million (Q4 2025), $44.1 million (Q3 2025), and $49.9 million (Q2 2025).